BeOne Medicines AG (FRA:49BA)

Market Cap	27.24B +8.1%
Revenue (ttm)	4.55B +40.2%
Net Income	244.38M
EPS	2.10
Shares Out	n/a
PE Ratio	111.47
Forward PE	48.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	236.00
Previous Close	236.00
Day's Range	236.00 - 236.00
52-Week Range	180.00 - 322.00
Beta	n/a
RSI	33.70
Earnings Date	May 7, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 12,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 49BA

Financial Performance

Financial numbers in USD